Numbers

The Numbers — AgeSA (AGESA.IS)

AGESA trades at roughly 6x trailing management-reporting earnings and 8x statutory (SFRS) earnings — a Turkish-insurance discount to global life peers that exists for three real reasons (hyperinflation accounting, float sensitivity to the policy rate, and 20% free float) and one that is harder to justify: a 55% five-year CAGR in book value per share against a market that keeps treating the stock as a cyclical bank proxy. The single chart most likely to rerate or derate AGESA is the Turkish policy rate. Net investment income now runs at ₺3.1B/year and covers the cost base twice over; when CBRT finishes the disinflation pivot, spread income compresses, and the pension fee engine plus life underwriting has to carry more of the load. That transition is the thesis.

Snapshot

179.98M shares, ₺42.5B market cap, trailing twelve-month statutory net profit ₺4.66B, FY2025 management-reporting net profit ₺6.84B. Book value per share ₺47.8 against a 2020 base of ₺3.8.

Quality scorecard — is the franchise durable?

No single red flag in the quality mosaic. Solvency is double the regulatory floor, expense ratio is improving every year, both franchise share positions are #1 among private insurers, and the 40/40/20 JV structure puts two deep-pocket sponsors behind the balance sheet. The one caveat is concentration: 60%+ of pension contribution flow runs through a single bank (Akbank), making the distribution engine a concentrated dependency rather than a diversified one.

1. How big, how fast, how profitable

Premium generation and technical income — the top of the funnel

Total gross written premium grew from ₺1.33B in 2020 to ₺24.37B in 2025 — an 18.3x nominal jump over five years. Technical profit after G&A compounded faster (17.8x), meaning unit profitability on each lira of premium has been preserved through hyperinflation despite opex growth.

Net profit — the bottom of the funnel

The gap between management-reporting and statutory earnings widens each year because TAS 29 inflation accounting deducts a monetary loss that inflates away the nominal profit. Statutory FY2025 net profit was ₺5.15B (vs ₺6.84B management) — a 27% haircut. Reported profit is real; the monetary loss is an accounting reclassification, not a cash cost.

Quarterly trajectory — the 2025 acceleration

Sequential revenue growth has been the signal: GWP rose every quarter through 2025, and management-reporting net profit in Q4 2025 was 62% higher than Q4 2024 even as the CBRT policy rate started falling.

2. Margin architecture — where the money comes from

The mix inside technical income

Five years ago, credit-linked life and return-of-premium savings produced roughly equal shares of technical income. By 2025, credit-linked life is the single largest technical engine (₺5.26B), pension is second (₺3.94B), and net investment income has scaled from ₺80M (2020) to ₺3.09B (2025) — a 39x jump. The business has shifted from an insurance company with a float attached to a float company with an insurance franchise attached.

Expense ratio — the operating leverage story

Expense ratio has compressed from 48.5% (2020) to 39.2% (2025) — a 930bp improvement in five years. This is the quiet compounding number. Every 100bp of expense-ratio improvement on a ₺12.9B technical income base adds ₺129M of technical profit; the cycle-insensitive leg of the story.

Value of New Business — forward-looking life economics

VNB rose 49% year-over-year in 2025 to ₺8.78B on an essentially unchanged 6.0% new-business margin — the life franchise is scaling volume without sacrificing economics. VNB alone exceeds full-year statutory net profit, meaning the embedded-value roll-forward is a meaningful and under-appreciated source of real return that sits outside the P&L.

3. Are the earnings real?

Asset base — the float that does the work

The ₺405B asset base as of 9M 2025 is financed by only ₺8.6B of shareholder equity — the rest is policyholder float (pension payables, mathematical reserves, insurance technical reserves). That 47x asset-to-equity ratio is what makes the ROE possible and what makes rate cuts dangerous; the spread on ₺381B of float is the P&L's dominant driver.

ROE — inflation-flattered but still compounding real book

Reported ROE has held 50–65% for four straight years. BVPS grew from ₺3.8 (2020) to ₺53.0 (2025), a 55% CAGR. Cumulative Turkish CPI over the same period compounded at roughly 36% annually — so real BVPS growth is closer to 14% per year. That is still exceptional for a life insurer, and better than the reported ROE number would suggest after you strip the inflation flatter.

4. Capital allocation — dividends are the main tool

Payout ratio has sat below 15% for five years because the regulator (SEDDK) caps distributions based on statutory capital. The proposed ₺1.0B dividend for 2025 (Board proposal, subject to AGM approval) is a meaningful jump and implies a forward yield of 2.35% at the current price — still modest for a Turkish listing but the highest payout since 2020. No buyback programme; there is none planned while free float is 20%.

5. Balance-sheet health

Solvency and leverage

Solvency I was 204% at FY2025 — more than double the regulatory minimum — despite the ₺1.0B dividend proposal. Capital adequacy is not the constraint on payout; statutory distributable reserves are.

Reserve backing

The ₺34.9B "Life insurance technical reserves" line item is trivial compared to the ₺354B of other payables (overwhelmingly pension-participant balances and unit-linked savings liabilities). AgeSA does not carry reinsurance recoverable risk in any material way; it runs a short-tail protection book where claims settle inside a year.

6. Valuation — three ways to price AGESA

Price vs its own recent history

The stock is up 202.6% over two years, compressed in a near-linear grind. Nothing here looks like a squeeze or a crash — it is earnings-driven repricing as the market absorbs quarter-after-quarter of 50%+ profit growth.

Rebased peer performance — AGESA vs Turkish insurance peers

Two-year total return: AGESA +202.6%, ANHYT +133.1%, TURSG +109.0%, ANSGR +36.7%, AKGRT +10.3% (RAYSG, a non-life peer that underwent heavy dilution, is excluded). AGESA has been the structural winner of the Turkish insurance complex through the rate cycle — outperforming the nearest pension-pure-play (ANHYT) by roughly 70 percentage points over the same window.

Multiple comparison — AGESA vs peers and vs itself

AGESA trades 42% below the global life-insurance median P/E despite a ROE that is three to four times the global peer median. The discount has three explanations — Turkey-risk, hyperinflation-accounting noise, and thin free float — but the gap is wider than any one of them justifies on its own.

Analyst consensus and fair value estimates

Dispersion is wide: the bull consensus (Investing.com, 4 analysts) sits 40.7% above spot at ₺332.59; the bear signal (Simply Wall St narrative model) sits 35% below at ₺154.50. The dispersion is the story — analysts disagree on whether 2024–25 spread income was a one-off boost from Turkish policy rates or a structural step-change in pension scale.

7. Peer comparison

Of the two listed private-pension pure-plays, AGESA trades at a modest P/E premium to ANHYT (9.1x vs 7.5x) but delivers a materially higher ROE (63% vs 48%) — the premium is earned. ANHYT has more pension-concentrated economics; AGESA has a better balanced franchise with stronger life-underwriting contribution. The state behemoth Türkiye Hayat is not listed, so there is no traded comparable for the full-market leader.

8. What rerates the stock — scenario ranges

The range that matters is ₺188 (bear) to ₺478 (bull), with a base of ₺308. The single most important input is the forward policy rate — everything else (premium growth, expense ratio, pension AuM) is modelable from current trends and leans positive.

Closing observations

The numbers confirm that AgeSA has built a genuine compounding engine: 55% CAGR on book value per share over five years, 930bp of expense-ratio compression, a pension AuM base growing faster than inflation, and a life-underwriting business that is now the single largest technical-income engine. The numbers contradict two pieces of the popular narrative — first, that AGESA is a bank proxy (it is a rate-sensitive float vehicle, but the fee business and underwriting margin are now structurally larger than either ANHYT or the 2020 version of AGESA); second, that hyperinflation accounting makes reported profits unreal (statutory SFRS profit is still ₺5.2B in 2025 at nine-plus times earnings, cheap by any global life standard). Watch next the Q1 2026 spread delta and the SPS (Supplementary Pension System) rollout timing — a one-quarter sequential decline in net investment income paired with accelerating pension contribution growth would validate the structural-step-change thesis; the opposite pattern would reset the stock toward the bear case.